PCSK9 and metabolic syndrome: The global approach to cardiovascular risk should be focused on lifestyle optimization (smoking cessation, diet, exercise, and weight loss), LDL-c lowering therapy (statins, ezetimibe, or PCSK9-inhibitors), and treatment of atherogenic dyslipidemia with additional therapy targeting TG/HDL-c abnormalities [12].